ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative6.45 B6.03 B5.89 B5.92 B6.75 B24.6 BRicerca e sviluppo5.3 B3.53 B3.52 B3.67 B4.25 B14.97 BReddito operativo-1.14 B5.13 B5.14 B5.95 B677 M16.9 BProventi non operativi, Totale442 M-65 M153 M705 M-246 M547 MOneri finanziari, al netto degli interessi capitalizzati137 M272 M308 M245 M214 M1.04 BProventi non operativi, esclusi gli oneri finanziari144 M-43 M-48 M-18 M23 M-86 MEntrate/uscite straordinarie161 M-294 M-107 M478 M-483 M-406 MUtile al lordo delle imposte3.89 B5.99 B6.49 B7.49 B4.97 B24.94 BQuota di utile——————Imposte456 M755 M954 M2.34 B-150 M3.9 BInteressi di minoranza——————Altri proventi/oneri al netto delle imposte——————Utile netto al lordo delle attività cessate3.43 B5.24 B5.54 B5.15 B5.12 B21.04 BAttività cessate0———0—Utile netto3.43 B5.24 B5.54 B5.15 B5.12 B21.04 BRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari3.43 B5.24 B5.54 B5.15 B5.12 B21.04 BUtile base per azione (EPS base)1.422.172.32.142.128.73Utile diluito per azione (EPS diluito)1.412.142.292.122.088.63Numero medio di azioni ordinarie in circolazione2.41 B2.41 B2.41 B2.41 B2.41 B—Azioni diluite in circolazione2.43 B2.45 B2.42 B2.43 B2.43 B—EBITDA777 M7.12 B5.97 B5.23 B2.7 B21.03 BEBIT-1.14 B5.13 B5.14 B5.95 B677 M16.9 BCosto del fatturato7.13 B8.11 B7.63 B7.3 B7.97 B31 BAltri costi del venduto——————Ammortamento e svalutazione (liquidità)1.9 B2 B1.94 B1.78 B2.01 B7.74 B
Johnson & Johnson Common Stock
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey.
The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments.
The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000.